A replication-incompetent PB2-knockout influenza a virus vaccine vector

Journal of Virology

Volumn 86, Issue 8, 2012, Pages 4123-4128

  Victor, Sylvia T ^a   Watanabe, Shinji ^b   Katsura, Hiroaki ^a   Ozawa, Makoto ^a,c   Kawaoka, Yoshihiro ^a,b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; INFECTION RESISTANCE; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; WEIGHT CHANGE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BODY WEIGHT; DOGS; FEMALE; GENETIC VECTORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; TURBINATES; VIRUS REPLICATION;

INFLUENZA A VIRUS; MURINAE; MUS; ORTHOMYXOVIRIDAE;

EID: 84861392547     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06232-11     Document Type: Article

References (20)

1. Cox RJ, Brokstad KA, Ogra P. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59:1-15.
2. DuBridge RB, et al. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.
3. Fiore AE, et al. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recommend. Rep. 59:1-62.
4. Fulvini AA, et al. 2011. Gene constellation of influenza A virus reassortants with high growth phenotype prepared as seed candidates for vaccine production. PLoS One 6:e20823.
5. Halperin SA, et al. 2002. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20:1240-1247.
6. Hampson AW. 2008. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann. Acad. Med. Singapore 37:510-517.
7. Hardy CT, Young SA, Webster RG, Naeve CW, Owens RJ. 1995. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. Virology 211:302-306.
8. Hatakeyama S, et al. 2005. Enhanced expression of an α 2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J. Clin. Microbiol. 43:4139-4146.
9. Iwatsuki-Horimoto K, et al. 2011. Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan. Clin. Vaccine Immunol. 18:860-866.
10. Katz JM, Wang M, Webster RG. 1990. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J. Virol. 64:1808-1811.
11. Kida H, Brown LE, Webster RG. 1982. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology 122:38-47.
12. Lin YP, Gregory V, Bennett M, Hay A. 2004. Recent changes among human influenza viruses. Virus Res. 103:47-52.
13. Moss RB, Davey RT, Steigbigel RT, Fang F. 2010. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. J. Antimicrob. Chemother. 65:1086-1093.
14. Muramoto Y, et al. 2006. Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions. J. Virol. 80:2318-2325.
15. Neumann G, et al. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. U. S. A. 96:9345-9350.
16. Ozawa M, et al. 2011. Replication-incompetent influenza A viruses that stably express a foreign gene. J. Gen. Virol. 92:2879-2888.
17. Palese P, Garcia-Sastre A. 2002. Influenza vaccines: present and future. J. Clin. Invest. 110:9-13.
18. Robertson JS. 1993. Clinical influenza virus and the embryonated hen's egg. Rev. Med. Virol. 3:97-106.
19. Robertson JS, et al. 1991. Sequence analysis of the haemagglutinin (HA) of influenza A (H1N1) viruses present in clinical material and comparison with the HA of laboratory-derived virus. J. Gen. Virol. 72:2671-2677.
20. Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y. 2002. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J. Virol. 76:767-773.